Status:
COMPLETED
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Lymphoma, Small Lymphocytic
Lymphocytic Leukemia, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This purpose of this study is to assess the toxicity and the rate of complete and overall response using fludarabine, rituximab, and alemtuzumab to treat patients with B-chronic lymphocytic leukemia o...
Detailed Description
Immunotherapy, or treatments that work by boosting immune function in the body, such as monoclonal antibodies have shown some efficacy against different types of leukemia. Researchers have learned to ...
Eligibility Criteria
Inclusion
- Must have B-CLL/SLL
- active disease
- \>=1 prior systemic therapy
- ECOG PS 0-2.
Exclusion
- Pregnant or nursing women
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00143065
Start Date
August 1 2005
End Date
July 1 2009
Last Update
February 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University
Columbus, Ohio, United States, 43210